Tests cemiplimab and dupilumab before surgery in early lung cancer
Tests two drugs given before surgery in adults with early non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
Key facts
- Where
- Montreal, CanadaSee the 2 sites
Where in Canada
- Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaNot yet recruiting
- CHUMMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT06743581
- Record updated
- 17 August 2026
- Original description
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Phase 1b focuses on safety and feasibility, using a 3+3 design to monitor dose-limiting toxicities (DLTs), while Phase 2a assesses the major pathological response (MPR) rate with a Simon's two-stage minimax design. Secondary endpoints include event-free survival, overall survival, and translational objectives such as deep immune monitoring from patient samples, with the trial expected to enroll 24 patients at CHUM over five years.Read full original descriptionShow less
Phase I/II Study of Combined Treatment With Cemiplimab (Anti-PD-1) and Dupilumab (Anti-IL-4R) in Patients With Early-stage, Resectable NSCLC
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Phase 1b focuses on safety and feasibility, using a 3+3 design to monitor dose-limiting toxicities (DLTs), while Phase 2a assesses the major pathological response (MPR) rate with a Simon's two-stage minimax design. Secondary endpoints include event-free survival, overall survival, and translational objectives such as deep immune monitoring from patient samples, with the trial expected to enroll 24 patients at CHUM over five years.
Inclusion: Histological confirmation of NSCLC is required before treatment (however, patients with a smoking history and radiographic findings suggestive of NSCLC may consent prior to biopsy to combine research and diagnostic procedures; Age ≥ 18 years; ECOG performance status 0-1; Determined to be a surgical candidate for tumor resection by a multidisciplinary team; Women of childbearing potential and men must use approved contraception during the study and for 4 months post-treatment. Pregnancy or suspected pregnancy must be reported immediately; Adequate organ and marrow function; Pre-treatment biopsies are mandatory, and tumors must be T1b or larger (>1cm) and amenable to biopsy as determined by a multidisciplinary team; Patients must consent to provide blood at designated study time points; Patients must consent to core needle biopsies (at least 3 samples, as deemed safe by the performing surgeon/radiologist) prior to treatment initiation.
Exclusion: History of autoimmune disorders or use of immunomodulatory drugs (including dupilumab) within 2 months prior to treatment initiation; Use of immunosuppressive drugs or systemic steroids within 7 days prior to treatment, except chronic steroids ≤10mg prednisone or equivalent; Prior chemotherapy or radiotherapy for another primary tumor, or prior locoregional therapy to the target lesion. Therapy for a different cancer is acceptable; Progressive malignancy requiring active treatment, except for certain stable cancers treated with curative intent; Active autoimmune disease requiring systemic treatment in the past year, excluding replacement therapies like thyroxine or insulin; Metastatic disease where surgery would not have curative intent; Uncontrolled illness, including active infections requiring antibiotics, symptomatic heart failure, unstable angina, or psychiatric/social conditions impeding study compliance; HIV infection with detectable viral load or not on a stable HAART regimen; Active Hepatitis B or C (PCR-detectable); History of allogeneic hematopoietic or solid organ transplantation; Documented hypersensitivity to protein therapeutics; Any condition, therapy, or abnormality that may interfere with trial results, patient participation, or their best interest as per the investigator's judgment; No smoking history or confirmed tissue or ctDNA evidence of actionable driver alterations (e.g. EGFR mutation, ALK, or ROS1 rearrangements); Pregnancy or nursing, due to potential harm to the fetus or infant.